← All trials
NCT05816356
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 24, 2023
- Primary completion
- May 16, 2023
- Completion date
- Oct 10, 2023
- First posted
- Apr 18, 2023
- Last posted
- Sep 7, 2023
- Enrollment
- 10
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- EpiDestiny, Inc.Lead sponsor
- Worldwide Clinical TrialsCollaborator
- Worldwide Clinical TrialsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.